Skip to main content
PACB
NASDAQ Industrial Applications And Services

PacBio Reports Narrower Q1 Adjusted Loss, Flat Revenue, and Strategic Progress

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$1.55
Mkt Cap
$498.297M
52W Low
$0.851
52W High
$2.73
52W Position info
82% above low
Off High info
43% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

PACB sits 82% above its 52-week low of $0.851.

Summary

Pacific Biosciences reported a narrower non-GAAP net loss for Q1 2026, exceeding analyst expectations, while total revenue remained flat. The company also strengthened its balance sheet with a $48.1 million asset sale and announced strategic collaborations.


Key Events · Earnings and Guidance · PACB

  • Q1 Non-GAAP Net Loss Narrows Significantly

    Reported a non-GAAP net loss of $35.9 million for Q1 2026, a substantial improvement from $44.4 million in Q1 2025, and narrower than analyst expectations.

  • Revenue Flat Year-over-Year with Consumable Growth

    Total revenue for Q1 2026 was $37.2 million, consistent with Q1 2025, driven by increased consumable revenue despite lower instrument sales.

  • Balance Sheet Strengthened by Asset Sale

    Completed the sale of short-read sequencing assets, generating approximately $48.1 million in net cash proceeds, which improved the company's cash position.

  • Strategic Collaborations and Product Expansion

    Announced selection by Basecamp Research for its Trillion Gene Atlas and expanded the SPRQ-Nx beta program with plans for a broad commercial rollout later this month.


Analysis · PACB · Industrial Applications And Services

This 8-K details Pacific Biosciences' first-quarter financial results, showing a significantly narrower non-GAAP net loss of $35.9 million, which beat analyst expectations. While total revenue remained flat year-over-year at $37.2 million and instrument sales were lower than anticipated, consumable revenue saw growth. The company also strengthened its balance sheet by completing the sale of short-read sequencing assets, generating approximately $48.1 million in net cash proceeds. Strategic highlights include a major collaboration with Basecamp Research and the expansion of the SPRQ-Nx beta program, with a broad commercial rollout planned. Investors will likely view the improved operational efficiency and strategic advancements positively, despite the flat top-line growth.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 45% of the 1400 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PACB was trading at $1.55 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $498.3M. The 52-week trading range was $0.85 to $2.73. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PACB - Latest Insights

PACB
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.54
Real-time Price: $2.25 info
Change: -$0.2882 (-11%) info
Market Cap: $700.923M info
PACB
Nov 04, 2026, 5:41 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.60
Real-time Price: $2.25 info
Change: -$0.3482 (-13%) info
Market Cap: $700.923M info
PACB
Nov 04, 2026, 4:09 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.68
Real-time Price: $2.25 info
Change: -$0.4282 (-16%) info
Market Cap: $700.923M info
PACB
Nov 04, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.57
Real-time Price: $2.25 info
Change: -$0.3182 (-12%) info
Market Cap: $700.923M info
PACB
Aug 06, 2026, 5:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.16
Real-time Price: $2.25 info
Change: +$1.09 (+94%) info
Market Cap: $700.923M info